Search results

Reducing the duration of treatment from six to four months: this is the new recommendation from the World Health Organization (WHO) for non-severe forms (NS) of of drug susceptible tuberculosis in children. Epicentre is currently assessing the feasibility and acceptability of this short course treatment in Uganda and in the Philippines, two of the early adopters of these recommendations. This study is part of Médecins Sans Frontières' (MSF) TACTiC project, which aims to improve the diagnosis and management of pediatric tuberculosis, while facilitating the integration of the latest WHO guidelines. In the Philippines, the study has just begun in partnership with the Manila Department of Health.

While the first malaria vaccines, RTS,S/AS01and R21/Matrix-M™, mark a major step forward in the fight against this disease, questions remain about the best administration strategy to maximize their impact, particularly in areas of seasonal malaria transmission. Epicentre is collaborating on two clinical trials, one in Chad with MSF and the other in Burkina-Faso and Mali with local research teams to compare two R21/Matrix-M™ vaccine administration strategies. Objective: to identify the most optimal strategy for implementing these vaccines to reduce malaria morbidity in children under the age of 5.